Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses
L Calabresi, D Donati, F Pazzucconi, CR Sirtori… - Atherosclerosis, 2000 - Elsevier
Elevations of plasma cholesterol and/or triglycerides, and the prevalence of small, dense
LDL particles remarkably increase coronary risk in patients with familial combined
hyperlipidemia (FCHL). A total of 14 FCHL patients were studied, to investigate the ability of
Omacor, a drug containing the n-3 fatty acids eicosapentaenoic and docosahexaenoic acid
(EPA and DHA), to favorably correct plasma lipid/lipoprotein levels and LDL particle
distribution. The patients received four capsules daily of Omacor (providing 3.4 g EPA+ DHA …
LDL particles remarkably increase coronary risk in patients with familial combined
hyperlipidemia (FCHL). A total of 14 FCHL patients were studied, to investigate the ability of
Omacor, a drug containing the n-3 fatty acids eicosapentaenoic and docosahexaenoic acid
(EPA and DHA), to favorably correct plasma lipid/lipoprotein levels and LDL particle
distribution. The patients received four capsules daily of Omacor (providing 3.4 g EPA+ DHA …